Home/Filings/4/0001562180-25-003658
4//SEC Filing

KOCH KEVIN 4

Accession 0001562180-25-003658

CIK 0001710072other

Filed

May 6, 8:00 PM ET

Accepted

May 7, 9:10 PM ET

Size

12.7 KB

Accession

0001562180-25-003658

Insider Transaction Report

Form 4
Period: 2025-05-01
KOCH KEVIN
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-05-01+10,41724,895 total
  • Sale

    Common Stock

    2025-05-02$16.45/sh4,276$70,35820,619 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-05-0110,4170 total
    Exercise: $0.00From: 2025-05-01Exp: 2032-05-01Common Stock (10,417 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    26,410
  • Common Stock

    (indirect: By Trust)
    26,410
  • Common Stock

    (indirect: See Footnotes)
    26,410
  • Common Stock

    (indirect: By Trust)
    26,410
  • Common Stock

    (indirect: By LLC)
    259,554
Footnotes (2)
  • [F1]Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
  • [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.84, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Edgewise Therapeutics, Inc.

CIK 0001710072

Entity typeother

Related Parties

1
  • filerCIK 0001185829

Filing Metadata

Form type
4
Filed
May 6, 8:00 PM ET
Accepted
May 7, 9:10 PM ET
Size
12.7 KB